CTEC

CTEC is a high-tech enterprise dedicated to the research, development, production, and sales of biomaterials for medical use, such as artificial corneas and artificial brain membranes. The company’s original innovation and self-developed product, "Acellular Corneal Graft," was approved for registration by the National Medical Products Administration (NMPA) in September 2019 after review. In its news release, the NMPA evaluated our product, stating, "Compared with similar products already on the market, the acellular treatment method used in this product is milder, allowing the lamellar structure of the obtained corneal stroma to remain relatively intact while removing a significant amount of antigenic components. The approval of this product provides a new option for the treatment of fungal corneal ulcers that do not involve the full thickness." The transparency rate of the "Acellular Corneal Graft" exceeds 90%. Leading ophthalmology experts in China have praised it for its "rapid epithelial growth, low immune rejection, effective infection control, and high graft transparency." It is the world's first product to date to use graft transparency rate as an evaluation index, establishing CTEC at the international forefront of this technological field.